Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: Results of the BC2001 Trial (CRUK/01/004)

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 2, 2013, Pages 261-269

  Huddart, Robert A ^a,b   Hall, Emma ^a   Hussain, Syed A ^c   Jenkins, Peter ^d   Rawlings, Christine ^e   Tremlett, Jean ^f   Crundwell, Malcolm ^f   Adab, Fawzi A ^g   Sheehan, Denise ^f   Syndikus, Isabel ^h   Hendron, Carey ⁱ   Lewis, Rebecca ^a   Waters, Rachel ^a   James, Nicholas D ⁱ  

^a Institute of Cancer Research   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^e UK   (United Kingdom)

^f South Devon Healthcare NHSFT ^*  (United Kingdom)

^g UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^h CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENCE INTERVAL; FACTORIAL DESIGN; LATE SIDE EFFECTS; LOCOREGIONAL CONTROL; LOCOREGIONAL RECURRENCE; METHODS AND MATERIALS; RADIATION THERAPY ONCOLOGY GROUPS; STATISTICALLY SIGNIFICANT DIFFERENCE;

CHEMOTHERAPY; DISEASES; MUSCLE; TOXICITY; TUMORS;

RADIOTHERAPY;

FLUOROURACIL; MITOMYCIN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BLADDER CAPACITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYSTECTOMY; CYSTITIS; DIARRHEA; DYSURIA; FACTORIAL DESIGN; FEMALE; HEMATURIA; HUMAN; INTENTION TO TREAT ANALYSIS; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; NOCTURIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE REDUCTION; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; STANDARD; SURVIVAL RATE; URETHRA STRICTURE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CHEMORADIOTHERAPY; CONFIDENCE INTERVALS; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SAMPLE SIZE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84882788665     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.06.2044     Document Type: Article

References (22)

1. International Agency for Research on Cancer. GLOBOCAN 2008. Available at: http://globocan.iarc.fr. Accessed August 24, 2010.
2. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients J Clin Oncology 19 2001 666 675
3. C. Rodel Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results J Clin Oncology 20 2002 3061 3071
4. National Institute for Clinical Excellence Guidance on Cancer Services. Improving Outcomes in Urological Cancers: The Manual 2002 NICE London
5. P. Cooke, J. Dunn, and T. Latief Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer Eur Urol 38 2000 279 286
6. W. Duncan, and P.M. Quilty The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy Radiother Oncol 7 1986 299 310
7. B.H. van der Werf-Messing, and W.L. van Putten Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50%) Int J Radiat Oncol Biol Phys 16 1989 369 371
8. R. Cowan, C. McBain, and W. Ryder Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy Int J Radiat Oncol Biol Phys 59 2004 197 207
9. B. Emami, J. Lyman, and A. Brown Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1991 109 122
10. R. Huddart, A. Norman, and M. Shahidi The effect of reducing the high dose volume on toxicity of radiotherapy in the treatment of bladder cancer Br J Cancer 80 Suppl. 2 1999 A3.10
11. S.A. Hussain, D.D. Moffitt, and J.G. Glaholm A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer Ann Oncol 12 2001 929 935
12. N.D. James, S.A. Hussain, and E. Hall Radiotherapy with or without chemotherapy in muscle invasive bladder cancer N Engl J Med 366 2012 1477 1488
13. L.H. Sobin, and I.D. Fleming TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer Cancer 80 1997 1803 1804
14. Cancer Therapy Evaluation Program Common Toxicity Criteria, Version 2.0 1998 Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services Bethesda, MD
15. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
16. P. Rubin, L.S. Constine, and L.F. Fajardo RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system Int J Radiat Oncol Biol Phys 31 1995 1041 1042
17. J.A. Efstathiou, K. Bae, and W.U. Shipley Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06 J Clin Oncol 27 2009 4055 4061
18. F. McDonald, E. Hall, and N. James Defining bowel dose constraints for bladder radiotherapy: Using data from patients entered into phase III randomised trial Eur J Cancer Suppl 7 2009 163 164
19. M.A. Tunio, A. Hashmi, and A. Qayyum Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience Int J Radiat Oncol Biol Phys 82 2012 e457 e462
20. M.K. Gospodarowicz, N.V. Hawkins, and G.A. Rawlings Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis J Urol 142 1989 1448 1453 discussion 1453-4
21. J.A. Efstathiou, D.Y. Spiegel, and W.U. Shipley Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience Eur Urol 61 2012 705 711
22. S. Lalondrelle, and R. Huddart Improving radiotherapy for bladder cancer: An opportunity to integrate new technologies Clin Oncol (R Coll Radiol) 21 2009 380 384